Track all markets on TradingView
FDA To Revisit Regeneron/Sanofi’s Dupixent For Rare Skin Disease
Media

FDA To Revisit Regeneron/Sanofi’s Dupixent For Rare Skin Disease

  • November 15, 2024
  • 5 Views

Regeneron and Sanofi’s Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025.

read more

​ 

​Regeneron and Sanofi’s Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025.
read more 

Share This Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.